Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study
- 1 December 2017
- journal article
- research article
- Published by Mary Ann Liebert Inc in Metabolic Syndrome and Related Disorders
- Vol. 15 (10), 515-520
- https://doi.org/10.1089/met.2017.0095
Abstract
Background: Weight loss is often nonsustainable after liraglutide cessation. The present study is the first insight into the potential prevention of weight regain in obese subjects who have been withdrawn from liraglutide. We evaluated whether dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in adjunct to metformin prevents body weight regain more effectively than metformin alone in obese polycystic ovary syndrome (PCOS) previously treated with liraglutide. Methods: A 12-week prospective randomized open-label study was conducted with 24 obese women with PCOS who had been pretreated with liraglutide 3.0 mg due to antiobesity management (aged 34.3 ± 6.8 years, body mass index [BMI] 36.3 ± 5.2 kg/m2, mean ± standard deviation). They were randomized to combined treatment (COMBO) with sitagliptin 100 mg per day (QD) and metformin (MET) 1000 mg twice daily (BID) (n = 12) or MET 1000 mg BID (n = 12). Lifestyle intervention was promoted in both groups. The primary outcome was change in anthropometric measures of obesity. Results: Women treated with MET regain 4.7 ± 2.7 kg (P = 0.002) compared with a 0.9 ± 2.5 kg in COMBO (P = 0.147). BMI increased for 1.7 ± 0.9 kg/m2 in MET (P = 0.002) compared with 0.3 ± 0.8 kg/m2 increase in COMBO (P = 0.136). MET group regain 4.5% ± 2.5% of body weight as opposed to 0.8% ± 2.6% in COMBO. The between-treatment differences were significant for weight change (P < 0.001), percentage of weight change (P < 0.001), and BMI change (P < 0.001). Greater ability to resist emotional eating was demonstrated in COMBO. Conclusion: Sitagliptin in adjunct to metformin prevented weight regain in obese women with PCOS previously treated with liraglutide.Keywords
This publication has 28 references indexed in Scilit:
- The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implicationsDiabetes, Obesity and Metabolism, 2013
- Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetesCardiovascular Diabetology, 2012
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic ReviewClinical Therapeutics, 2012
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experienceVascular Health and Risk Management, 2010
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 DiabetesJAMA, 2010
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Gastric emptying of solids in humans: improved evaluation by Kaplan-Meier plots, with special reference to obesity and genderEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- The three-factor eating questionnaire to measure dietary restraint, disinhibition and hungerJournal of Psychosomatic Research, 1985